Latest Content

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

Spot ICU delirium early with MD‑MOSAIC—an exam for ventilated patients that sharpens diagnosis, prevents harm, and improves outcomes.

AI chatbots reshape therapy, pushing clinicians to unite around common change principles and connection.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

Round on the latest news in psychiatry from the last week.

Adial seeks FDA priority voucher to speed AD04 review, a biomarker-guided therapy aiming to curb heavy drinking in alcohol use disorder.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Explore GLP-1 agonists and their "truly transformative" role in psychiatry in this podcast.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

AXS-05 for Alzheimer disease agitation nears FDA decision date.